Targeting Degradation of EGFR through the Allosteric Site Leads to Cancer Cell Detachment-Promoted Death

Targeting epidermal growth factor receptor (EGFR) with tyrosine kinase inhibitors (TKI) has been widely exploited to disrupt aberrant phosphorylation flux in cancer. However, a bottleneck of potent TKIs is the acquisition of drug resistance mutations, secondary effects, and low ability to attenuate...

Descripción completa

Detalles Bibliográficos
Autores principales: Iradyan, Melkon, Iradyan, Nina, Hulin, Philippe, Hambardzumyan, Artur, Gyulkhandanyan, Aram, Alves de Sousa, Rodolphe, Hessani, Assia, Roussakis, Christos, Bollot, Guillaume, Bauvais, Cyril, Sakanyan, Vehary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721407/
https://www.ncbi.nlm.nih.gov/pubmed/31374910
http://dx.doi.org/10.3390/cancers11081094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721407/
https://www.ncbi.nlm.nih.gov/pubmed/31374910
http://dx.doi.org/10.3390/cancers11081094

Ejemplares similares